Cambridge, UK, 5 May 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research.
Cambridge, UK, 15 April 2021 – Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
London, UK, 16 March 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington’s disease (HD). The grant will support Alchemab in its pioneering collaboration with Medicines Discovery Catapult.
| Alchemab Therapeutics 55-56 Russell Square London WC1B 4HP |
Meditrina Building 260 Babraham Research Campus Cambridge CB22 3AT |
© 2021 Alchemab. All rights reserved.
Casting a spell: The Killer50 Magic Circle is unveiled
/in In The News /by resilience5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices.
Read full article
Cambridge companies help develop Covid antibody cocktail
/in In The News /by resilience1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail.
Read full article
Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium
/in In The News /by resilience29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool of over 600 novel candidates and identified a set of antibodies with the greatest potential.
Read full article